The Report EpiCast Report: Alzheimers Disease - Epidemiology Forecast to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz
Albany, NY -- (SBWIRE) -- 04/23/2015 -- AD is an irreversible, neurodegenerative brain disease of the elderly, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity. Similar to AD, mild cognitive impairment (MCI) is also a condition of the elderly in which there is a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia.
View Full Report at http://www.marketresearchreports.biz/analysis/269277
To forecast the total prevalent cases of AD in adults ages =60 years in the 9MM during the forecast period (2013-2023), GlobalData epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSM-III-R) to diagnose dementia, and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria to diagnose AD. Similarly, to forecast the total prevalent cases of MCI in the 9MM, GlobalDatas epidemiologists selected country-specific studies that defined MCI as a "slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills, but no dementia." Additionally, GlobalData epidemiologists kept the forecast methodology consistent across the 9MM in order to allow for a meaningful comparison of the total prevalent cases between the markets.
GlobalData epidemiologists forecast that by 2023, there will be approximately 17.38 million total prevalent cases of AD across the 9MM covered in this analysis. GlobalData epidemiologists expect a 34.3% increase in the total prevalent cases of AD in the 9MM over the next decade. Similarly, GlobalData epidemiologists forecast that the total prevalent cases of MCI in the 9MM will increase from 82.25 million cases in 2013 to 108.41 million cases in 2013 at a decadal growth rate of 31.80%.
Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/269277
The Alzheimers disease (AD) EpiCast Report provides an overview of the risk factors and global trends of AD in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, China, and India). The series also includes a 10-year epidemiological forecast for the total prevalent cases of AD segmented by sex, age, and severity in these markets. In addition, the report includes a 10-year epidemiological forecast for the total prevalent cases of mild cognitive impairment (MCI) segmented by sex and age in these markets.
The AD epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.
Reasons to buy
Develop business strategies by understanding the trends shaping and driving the global AD market.
Quantify patient populations in the global AD market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AD therapeutics in each of the markets covered.
Identify the percentage of AD prevalent cases by severity and identify the number of cases with MCI.
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Related Reports 9
2.2 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.2.1 A family history of Alzheimer's increases the risk of developing the disease by 7.5 times 12
3.2.2 The APOE 4 allele triples the risk for AD 13
3.2.3 Cardiovascular risk factors in midlife significantly increase the risk of developing AD in later life 13
3.2.4 The incidence and prevalence of AD double every five years after age 65 years 14
3.2.5 Diabetes doubles the risk of AD in men, but only marginally affects the risk in women 14
3.2.6 Women are 1.5 times more likely to develop AD than men 15
3.2.7 Depression triples the risk for AD, and is the most common comorbidity 15
3.2.8 Up to 70% of AD patients also suffer from anxiety 16
3.2.9 Psychosis and agitation are common comorbidities in Alzheimer's patients 16
3.3 Global Trends 16
3.3.1 US 17
3.3.2 5EU 18
3.3.3 Japan 20
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Office: State Tower
90 State Street, Suite 700
Albany, NY 12207
USA: Canada Toll Free: 866-997-4948